Search Results
Jan 28, 2026, 11:36 ET St. Louis Children's Hospital launches "I Am Proof" fundraising campaign to transform the future of children's health
centers of excellence as part of the Children's Discovery Institute, including the Center for Brain Development and Neurological Disorders; Center for Gene and Cell-Based Therapies; Center for Pediatric Immunology; Center for Pediatric Pulmonary Disease and Asthma; Center for Rare, Undiagnosed and Genetic
More news about: St. Louis Children's Hospital
Jan 28, 2026, 09:00 ET REPROCELL Launches StemEdit - Clinical Gene Editing Services and New iPSC Lines Using AI-Designed editing tools
Jan. 28, 2026 /PRNewswire/ -- REPROCELL today announced the commercial launch of StemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveraging OpenCRISPR-1™, an AI-designed genome editing system licensed from Profluent (Emeryville,
More news about: REPROCELL USA
Jan 28, 2026, 09:00 ET REPROCELL Launches StemEdit - Clinical Gene Editing Services and New iPSC Lines Using AI-Designed editing tools
Jan. 28, 2026 /PRNewswire/ -- REPROCELL today announced the commercial launch of StemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveraging OpenCRISPR-1™, an AI-designed genome editing system licensed from Profluent (Emeryville,
More news about: REPROCELL USA
Jan 28, 2026, 09:00 ET New Passport Study Shows Cities Shifting Toward Compliance-First Parking Strategies
years."Disconnected systems and limited staff capacity often force teams into manual workarounds, driving slower translation of insights into action," added Gene Rohrwasser, CTO of Passport. "As systems become more integrated, real-time, and data becomes more actionable, compliance-first strategies will be easier
More news about: Passport
Jan 28, 2026, 08:38 ET New Preeclampsia Research Funded to Investigate Genetic Targets and Possible Therapeutics
developmental gene regulation. She is a recipient of an NIH K99/R00 Pathway to Independence Award. Her laboratory investigates how non-coding genetic variation regulates gene expression and contributes to the pathogenesis of preeclampsia, with the goal of identifying enhancer-mediated gene regulatory mechanisms
More news about: Preeclampsia Foundation
Jan 28, 2026, 08:00 ET Stellaromics Expands Pyxa™ 3D Spatial Transcriptomics Beta Program with Installation at Emory University School of Medicine
physiology and function. By integrating nucleic acid chemistry, spatial genomics, and computation, her lab aims to understand and ultimately manipulate gene expression to inform new therapeutic strategies for diseases in the brain and beyond.Dr. Shi's laboratory will use the Pyxa system to advance
More news about: Stellaromics
Jan 28, 2026, 08:00 ET Bionique Testing Laboratories Appoints Dr. Andy Bailey, Strengthening Global Biosafety Testing
Bionique offers analytical testing solutions and validation services to support drug development and ensure the safety of biopharmaceuticals, cell & gene therapies, and vaccines. Bionique is integral to the Biosafety Testing Services Unit of Asahi Kasei Bioprocess. To learn more about Bionique, visit
More news about: Bionique Testing Laboratories LLC
Jan 28, 2026, 07:30 ET REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
(clemidsogene lanparvovec)RGX-121 is a potential one-time gene therapy for the treatment of boys with MPS II, designed to deliver the iduronate-2-sulfatase (IDS) gene to the central nervous system (CNS). Delivery of the IDS gene within cells in the CNS could provide a permanent source of
More news about: REGENXBIO Inc.
Jan 28, 2026, 07:00 ET Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress
therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey,
More news about: Insmed Incorporated
Jan 28, 2026, 06:55 ET Independent Stanford Research Spotlights Fasting Mimicking Technology as a New Path for Crohn's Disease
pharmacologic options.Biological alignment:Exploratory analyses identified changes in inflammatory lipid mediators and immune-related gene expression consistent with improved disease activity.Short-term adjunctive use:Participants remained on prescribed medical
More news about: L-Nutra Inc.
Jan 28, 2026, 06:45 ET PROSPERITY BANCSHARES, INC.® REPORTS FOURTH QUARTER 2025 EARNINGS
of Texas Partners Bank and expect the transaction will be effective on February 1, 2026. In connection with the Southwest deal, we are pleased that Gene Dawson, Interim Chairman of Southwest Bancshares and Chairman of the nationally recognized Pape-Dawson engineering firm will be joining our Bank Board
More news about: Prosperity Bancshares, Inc.
Jan 27, 2026, 17:31 ET Pharma Conference Coverage Services: Real-Time Pharma Intelligence to Power Strategic Decision-Making
with real-time, accurate insights spanning multiple therapeutic domains, including competitor pipelines and clinical trial tracking, innovations in gene and cell therapy, market-entry strategies, and evolving regulatory and patent landscapes. Our intelligence empowers decision-makers to anticipate market
More news about: DelveInsight Business Research, LLP
Jan 27, 2026, 14:05 ET Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA
restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine
More news about: Anchor Line Partners
Jan 27, 2026, 09:00 ET Debut Unveils Biotech Active Delivering In-Office Skin Tightening Results in Topical Skincare
key skin-scaffolding protein essential for firmness. It also mitigates cellular stress by downregulating stress-related proteins and reversing adverse gene expression, promoting long-term dermal integrity and a visibly lifted appearance."This is the promise of biotechnology realized," said Joshua
More news about: Debut Biotechnology
Jan 27, 2026, 08:37 ET Dual Platform Options for Critical Single-Use Freeze and Thaw Operations from Meissner
microfiltration and therapeutic manufacturing systems for the development and manufacture of pharmaceuticals, therapeutics, biologics, and cell and gene therapies. For more information, visit
More news about: Meissner Corporation
Jan 27, 2026, 08:00 ET Minaris Announces Viral Clearance Laboratory Upgrade at Philadelphia Campus
executionPHILADELPHIA, Jan. 27, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, today announced an upgrade to
More news about: Minaris Advanced Therapies
Jan 26, 2026, 17:31 ET RET Fusion Targeted Therapies Market Set for Robust Growth by 2034 Amid Precision Oncology Shift | DelveInsight
The RET fusion-targeted therapy market is set for strong expansion, driven by growing awareness of the oncogenic role of RET gene fusions and encouraging clinical trial outcomes. With the approval of targeted agents such as selpercatinib and pralsetinib for RET fusion-positive tumors, oncology
More news about: DelveInsight Business Research, LLP
Jan 26, 2026, 10:16 ET Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
https://www.fda.gov/news-events/press-announcements/fda-increases-flexibility-requirements-cell-and-gene-therapies-advance-innovation
More news about: Equity Insider
Jan 26, 2026, 08:30 ET Immusoft Receives FDA Rare Pediatric Disease Designation for ISP-002 to treat Mucopolysaccharidosis Type II
California to fund stem cell and gene therapy research with the goal of accelerating treatments for patients with unmet medical needs. With $8.5 billion in funding allocated through both Proposition 71 in 2004 and Proposition 14 in 2020, CIRM supports stem cell and gene therapy discoveries from inception
More news about: Immusoft
Jan 26, 2026, 08:30 ET Avant Technologies Evaluating Advanced Cells for Diabetes Therapy at 15th Annual EPITA Symposium
transplanted insulin-producing cells from immune rejection without potential risks, such as tumor formation or infections that may be associated with gene editing and/or immunosuppression."While stem cell-derived beta cells undoubtedly represent a breakthrough in unlimited insulin sources, immune
More news about: Avant Technologies Inc.
Jan 25, 2026, 19:00 ET FDAの快挙間葉系間質細胞（MSC）初となる品質管理手順により、新たな治療基準を確立
ラダイムシフトを加速するものです。FDAは、MSCが分化ではなく、主に傍分泌シグナル伝達として機能するという最新の科学的知見に合致した基準の支持により、重要な規制上のギャップを埋めようと画策しています。また、International Society for Cell & Gene Therapyの最新ガイドラインとの整合性を担保することで、治験用新薬申請の合理化、臨床試験の信頼性向上、MSC製品評価における世界規模での調和を促進する態勢を整えています。
More news about: Tasly
Jan 25, 2026, 19:00 ET 미 FDA, 중간엽 기질세포(MSC) 첫 품질관리 기준 승인…세포치료 새 기준 제시
아닌, 파라크린 신호 전달(paracrine signaling)을 통해 주로 기능한다는 현대 과학적 이해에 부합하는 기준을 승인함으로써, FDA는 중대한 규제 공백을 메우게 됐다. 국제세포유전자치료학회(International Society for Cell & Gene Therapy)의 최신 가이드라인을 따르는 이번 조치는 임상시험계획 승인신청(IND) 절차를 간소화하고, 임상시험의 신뢰도를 높이며, MSC 제품 평가의 글로벌 표준화를 촉진할 것으로 기대된다.
More news about: Tasly
Jan 25, 2026, 19:00 ET Landmark FDA Move: First Quality Control Protocol for Mesenchymal Stromal Cells (MSCs) Sets New Therapeutic Standard
paracrine signaling, not differentiation—the FDA is closing a critical regulatory gap. This alignment with updated International Society for Cell & Gene Therapy guidelines is poised to streamline Investigational New Drug applications, enhance clinical trial reliability, and foster global harmonization
More news about: Tasly
Jan 25, 2026, 19:00 ET Langkah Bersejarah FDA: Protokol Pengendalian Mutu Pertama untuk "Mesenchymal Stromal Cells" (MSC) Jadi Standar Terapi Baru
sinyal parakrin, bukan melalui diferensiasi—FDA menutup kesenjangan regulasi. Keselarasan dengan pedoman terbaru International Society for Cell & Gene Therapy ini akan memperingkas pengajuan Investigational New Drug (IND), meningkatkan keandalan uji klinis, serta mendorong harmonisasi global
More news about: Tasly
Jan 25, 2026, 19:00 ET Argo Biopharma Announces First Patient Dosed in Phase 2b Trial of siRNA Therapeutic BW-20829 in Patients with Elevated Lp(a)
cardiovascular risk."BW-20829 is an siRNA therapeutic developed from Argo's proprietary RADS™ platform, and is designed to enable potent, durable gene silencing with differentiated safety and delivery characteristics through hepatic delivery. Argo Biopharma continues to advance a cardiovascular and
More news about: Argo Biopharmaceutical Co., Ltd